The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells

SARS-CoV-2 was shown to infect and persist in the human brain cells for up to 230 days, highlighting the need to treat the brain viral load. The CNS disposition of the antiCOVID-19 drugs: Remdesivir, Molnupiravir, and Nirmatrelvir, remains, however, unexplored. Here, we assessed the human brain phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleh, Mohammed A.A., Hirasawa, Makoto, Sun, Ming, Gülave, Berfin, Elassaiss-Schaap, Jeroen, de Lange, Elizabeth C.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710098/
https://www.ncbi.nlm.nih.gov/pubmed/36462547
http://dx.doi.org/10.1016/j.ejps.2022.106345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710098/
https://www.ncbi.nlm.nih.gov/pubmed/36462547
http://dx.doi.org/10.1016/j.ejps.2022.106345

Ejemplares similares